Probatebeta
Company

Akros Pharma

As of the edition of 20 October 2026, Akros Pharma runs 14 drugs, 1 of them marketed; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Marketed1
Active1
Went quiet6
Stopped4
Status not established2
Total14

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
Enarodustatnone listed0

A route B row is one company at one target.

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
ITK Tyrosine-protein kinase ITK/TSKRoute A
MTTP Microsomal triglyceride transfer protein large subunitRoute A
FFAR1 Free fatty acid receptor 1Route A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

See all 4 targets where Akros Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.

Where its trials are

  • Nutrition and metabolism: 11 trials led
  • Hormones: 6 trials led
  • Skin and connective tissue: 5 trials led

Targets where Akros Pharma has drugs

Other companies active in nutrition and metabolism